Compound News and Research

RSS

Case study sheds light on pathological course of Alzheimer's disease

A case study from the Swedish medical university Karolinska Institutet sheds light on the pathological course of Alzheimer's disease. The brain of the first Alzheimer's patient to display amyloids demonstrable with a PET scanner has been studied, both during progression of the disease and after death.

15 Dec 2010

Clinical trial investigates pomalidomide in only U.S. study for multiple myeloma

Multiple myeloma, a type of blood cancer in which malignant plasma cells are overproduced in the bone marrow, has led to an estimated 20,000 new diagnoses and 11,000 deaths in 2010. Patients with the disease, who have already failed previous treatments, may be considered for a currently enrolling Phase II study, examining a unique drug combination.

14 Dec 2010

Chimerix reports positive results from CMX157 Phase 1 clinical trial for HIV

Chimerix, Inc., a pharmaceutical company developing orally-available antiviral therapeutics, today announced first-in-human Phase 1 clinical trial results for CMX157 demonstrating a favorable safety, tolerability and drug distribution profile.

14 Dec 2010

Immunomedics, UCB initiate enrollment in EMBODY 1 epratuzumab Phase III study in SLE

Immunomedics Inc. and UCB today announced the enrollment of the first patient into EMBODY™ 1, one of two pivotal Phase III studies of epratuzumab in patients with moderate to severe systemic lupus erythematosus (SLE). Patient enrollment for EMBODY™ 2 has also begun.

14 Dec 2010

Mouse study shows flu virus infection may protect against asthma

In a paper that suggests a new strategy to prevent asthma, scientists at Children's Hospital Boston and their colleagues report that the influenza virus infection in young mice protected the mice as adults against the development of allergic asthma.

14 Dec 2010

Top-line results from Inhibitex's FV-100 Phase II clinical trial for treatment of shingles

Inhibitex, Inc. today reported top-line safety and efficacy data from its Phase II clinical trial of FV-100, an oral antiviral compound being developed to treat herpes zoster, more commonly referred to as shingles. The study was the first clinical trial to assess the antiviral activity of FV-100, included 350 shingles patients and compared two once-daily doses of FV-100 (200 mg and 400 mg) to an active control, valacyclovir, one of the most commonly-used antiviral drugs to treat shingles.

14 Dec 2010

Lilly suspends tasisulam global Phase III study in metastatic melanoma

Eli Lilly and Company announced today that it has suspended its global Phase III study evaluating tasisulam, an investigational, small-molecule anti-cancer compound, as a second-line treatment for those with unresectable or metastatic melanoma.

13 Dec 2010

Arena initiates dosing in APD811 Phase 1 clinical trial for pulmonary arterial hypertension

Arena Pharmaceuticals, Inc. announced today the initiation of dosing in a Phase 1 clinical trial of APD811, a novel oral drug candidate discovered by Arena that targets the prostacyclin receptor for the treatment of pulmonary arterial hypertension, or PAH.

10 Dec 2010

Serodus licenses selective serotonin-4 antagonist for potential heart failure treatment from Roche

Serodus AS today announced that it has entered into a license agreement with Roche for a selective serotonin-4 (5-HT4) antagonist for the potential treatment of heart failure (RO1160367).

10 Dec 2010

Simple molecular sensor color test to determine safe fluoride levels

Used in the proper amounts, it can make teeth stronger and aid in the treatment of osteoporosis. When excessive amounts are consumed, however, it can be a killer - a carcinogen that causes bone, lung and bladder cancers. The "it" is fluoride, a common additive in most American communities' drinking water and an ingredient in the vast majority of commercially produced adult toothpastes.

10 Dec 2010

Using buprenorphine to treat opioid-dependent pregnant women may result in healthier babies

Using buprenorphine instead of methadone — the current standard of care — to treat opioid-dependent pregnant women may result in healthier babies, suggests new findings from an international team led by Johns Hopkins researchers and published in the Dec. 9 issue of the New England Journal of Medicine.

10 Dec 2010

New molecular tools show promise for cleansing brain of amyloid plaques

New molecular tools developed at the University of Michigan show promise for "cleansing" the brain of amyloid plaques, implicated in Alzheimer's disease.

10 Dec 2010

Researchers find new light-activated platinum-based compound to kill cancer cells

When it comes to health care blue lights, are usually most useful on the top of ambulances but now new research led by the University of Warwick has found a way to use blue light to activate what could be a highly potent platinum-based cancer treatment.

10 Dec 2010

Zealand receives EUR 500,000 milestone payment from Helsinn Healthcare for ZP1846 development program

Zealand Pharma, a biopharmaceutical company dedicated to the discovery and development of innovative peptide drugs that recently listed on NASDAQ OMX, today announces the receipt of a EUR 500,000 (DKK 3.73 million) milestone payment as part of its license agreement with Helsinn Healthcare for the development of ZP1846 for the treatment of chemotherapy-induced diarrhoea. This milestone payment has no impact on the Company's outlook for 2010.

9 Dec 2010

Rexahn presents data from Serdaxin Phase IIa study at 49th ACNP Annual Meeting

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and central nervous system (CNS) therapeutics, today announced the presentation of data from its proof of concept study with lead CNS compound Serdaxin® at the 49th American College of Neuropsychopharmacologists (ACNP) Annual Meeting, held in Miami Beach, FL, December 5-9, 2010 at the Fountainbleau Resort.

9 Dec 2010

Researchers to study effect of resveratrol on impaired IGT in older prediabetic patients

Researchers at Albert Einstein College of Medicine of Yeshiva University have been awarded $600,000 from the American Diabetes Association to study the effect of resveratrol, a chemical compound most notably found in red wine and grapes, on impaired glucose tolerance in older adults.

9 Dec 2010

Anchor Therapeutics announces publication describing pepducin technology as novel approach to target GPCR

Anchor Therapeutics today announced the publication of new research in the Proceedings of the National Academy of Sciences USA. The paper describes the identification and characterization of a pepducin-based allosteric agonist that targets CXCR4, a chemokine G protein-coupled receptor found on hematopoietic stem cells and other bone marrow-derived cells.

9 Dec 2010

Clinical data of pomalidomide for treating patients with multiple myeloma presented at ASH 2010

Celgene International Sàrl today announced that its next IMiD compound, pomalidomide, was evaluated in three separate investigational trials of patients with multiple myeloma who were relapsed or refractory after prior treatments including lenalidomide, thalidomide and bortezomib. The clinical data were presented at the 52nd Annual Meeting of the American Society of Hematology in Orlando, Florida.

9 Dec 2010

Small molecules show promise in protecting brain cells against nerve-degenerative diseases

Investigators at Southern Methodist University and The University of Texas at Dallas have discovered a family of small molecules that shows promise in protecting brain cells against nerve-degenerative diseases such as Parkinson's, Alzheimer's and Huntington's, which afflict millions.

8 Dec 2010

GlycoMimetics highlights clinical, preclinical progress of GMI-1070 in sickle cell crisis at ASH 2010

GlycoMimetics, Inc., a clinical-stage biotechnology company developing a new class of glycobiology-based therapies for a broad range of indications, today announced that two oral presentations and two abstracts were delivered at the 52nd Annual Meeting of the American Society of Hematology in Orlando, Florida. The presentations and abstracts highlighted clinical and preclinical progress with GlycoMimetics's lead compound GMI-1070, now in Phase 2 clinical trials in sickle cell crisis.

8 Dec 2010

Compound News and Research

Case study sheds light on pathological course of Alzheimer's disease

Clinical trial investigates pomalidomide in only U.S. study for multiple myeloma

Chimerix reports positive results from CMX157 Phase 1 clinical trial for HIV

Immunomedics, UCB initiate enrollment in EMBODY 1 epratuzumab Phase III study in SLE

Mouse study shows flu virus infection may protect against asthma

Top-line results from Inhibitex's FV-100 Phase II clinical trial for treatment of shingles

Lilly suspends tasisulam global Phase III study in metastatic melanoma

Arena initiates dosing in APD811 Phase 1 clinical trial for pulmonary arterial hypertension

Serodus licenses selective serotonin-4 antagonist for potential heart failure treatment from Roche

Simple molecular sensor color test to determine safe fluoride levels

Using buprenorphine to treat opioid-dependent pregnant women may result in healthier babies

New molecular tools show promise for cleansing brain of amyloid plaques

Researchers find new light-activated platinum-based compound to kill cancer cells

Zealand receives EUR 500,000 milestone payment from Helsinn Healthcare for ZP1846 development program

Rexahn presents data from Serdaxin Phase IIa study at 49th ACNP Annual Meeting

Researchers to study effect of resveratrol on impaired IGT in older prediabetic patients

Anchor Therapeutics announces publication describing pepducin technology as novel approach to target GPCR

Clinical data of pomalidomide for treating patients with multiple myeloma presented at ASH 2010

Small molecules show promise in protecting brain cells against nerve-degenerative diseases

GlycoMimetics highlights clinical, preclinical progress of GMI-1070 in sickle cell crisis at ASH 2010

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News